- Trials with a EudraCT protocol (49)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
49 result(s) found for: Microangiopathy.
Displaying page 1 of 3.
EudraCT Number: 2020-005328-13 | Sponsor Protocol Number: ALXN1210-TMA-315 | Start Date*: 2021-10-04 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated wi... | ||||||||||||||||||
Medical condition: thrombotic microangiopathy associated with a trigger | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003168-22 | Sponsor Protocol Number: 2020/0206/HP | Start Date*: 2021-09-02 | |||||||||||
Sponsor Name:Rouen University Hospital | |||||||||||||
Full Title: Multicenter, uncontrolled pilot study evaluating the efficacy of eculizumab in the treatment of gemcitabine-induced thrombotic microangiopathies. | |||||||||||||
Medical condition: Thrombotic microangiopathies induced by gemcitabine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000144-61 | Sponsor Protocol Number: ALXN1210-TMA-313 | Start Date*: 2020-08-17 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) | |||||||||||||
Medical condition: Hematopoietic stem cell transplant-associated thrombotic microangiopathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Ongoing) SE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001736-30 | Sponsor Protocol Number: | Start Date*: 2011-11-30 |
Sponsor Name:Med. Univ. Wien, Klinik für Dermatologie | ||
Full Title: BOSENTAN FOR THE TREATMENT OF SKIN ULCERS IN DIABETIC MICROANGIOPATHY | ||
Medical condition: Bosentan for the treatment of skin ulcera in diabetic Microangiopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000761-16 | Sponsor Protocol Number: ALXN1210-TMA-314 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy... | |||||||||||||
Medical condition: hematopoietic stem cell transplant-associated thrombotic microangiopathy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000086-17 | Sponsor Protocol Number: AK901 | Start Date*: 2020-08-06 | ||||||||||||||||||||||||||
Sponsor Name:Akari Therapeutics Plc | ||||||||||||||||||||||||||||
Full Title: Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy | ||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003157-27 | Sponsor Protocol Number: Sobi.PEGCET-201 | Start Date*: 2021-12-17 | |||||||||||
Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL) | |||||||||||||
Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (... | |||||||||||||
Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) GR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004972-49 | Sponsor Protocol Number: CLFG316X2202 | Start Date*: 2016-03-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass... | |||||||||||||
Medical condition: Transplant associated microangiopathy (TAM) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000221-22 | Sponsor Protocol Number: BANDY 070112 | Start Date*: 2007-10-15 |
Sponsor Name:John Pernow | ||
Full Title: Effect of bosentan on macro- and microvascular function in patients with type 2 diabetes | ||
Medical condition: Type 2 diabetes and albuminuria. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002727-38 | Sponsor Protocol Number: OMS721-HCT-002 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||||||||||||
Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant... | |||||||||||||||||||||||
Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001032-11 | Sponsor Protocol Number: OMS721-TMA-001 | Start Date*: 2014-09-30 | |||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||
Full Title: A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombo... | |||||||||||||
Medical condition: Three forms of thrombotic microangiopathies (TMA): - atypical hemolytic uremic syndrome (aHUS) - hematopoietic stem cell transplant (HSCT)-associated TMA - thrombotic thrombocytopenic purpura (TTP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004430-42 | Sponsor Protocol Number: AHA-EMI | Start Date*: 2021-01-25 | ||||||||||||||||
Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
Full Title: Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial | ||||||||||||||||||
Medical condition: Acquired Hemophilia A (AHA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001872-54 | Sponsor Protocol Number: ARC1779−006 | Start Date*: 2009-01-24 | |||||||||||
Sponsor Name:Archemix Corp | |||||||||||||
Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy. | |||||||||||||
Medical condition: Thrombotic microangiopathy (TMA) disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005186-13 | Sponsor Protocol Number: CLNP023F12301 | Start Date*: 2021-08-26 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy | |||||||||||||
Medical condition: atypical hemolytic uremic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) SI (Ongoing) CZ (Ongoing) SK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001082-24 | Sponsor Protocol Number: ALN-CC5-004 | Start Date*: 2017-08-18 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome | |||||||||||||
Medical condition: Atypical Hemolytic Uremic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002796-28 | Sponsor Protocol Number: CEASESTIFFNESS | Start Date*: 2016-04-12 |
Sponsor Name:University Medical Center Groningen (UMCG) | ||
Full Title: The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. | ||
Medical condition: Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischem... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001208-39 | Sponsor Protocol Number: GALILEO242012 | Start Date*: 2012-05-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® vs. cOnve... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapy myocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-func... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004568-25 | Sponsor Protocol Number: BLAST | Start Date*: 2021-08-18 | |||||||||||
Sponsor Name:DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO) | |||||||||||||
Full Title: Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of Antiphospholipid Syndrome. | |||||||||||||
Medical condition: APS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001157-27 | Sponsor Protocol Number: 2017_52-REGALIA | Start Date*: 2018-11-22 |
Sponsor Name:CHRU of Lille | ||
Full Title: Reversing poor graft function with eltrombopag after allogeneIc hematopoietic cell transplantation : a prospective, phase II study by the SFGM-TC. | ||
Medical condition: Poor Graft Function (PGF) after allogeneic hematopoietic cell transplantation (allo-HCT). PGF is commonly defined as follows: one or several significant cytopenias after allo-HCT persisting or deve... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002179-32 | Sponsor Protocol Number: BO41423 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS | |||||||||||||
Medical condition: Mild or moderate hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) DE (Ongoing) NL (Ongoing) PL (Completed) BE (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.